

The oxysterol receptor GPR183 in inflammatory bowel diseases

Benjamin Misselwitz¹⁾, Annika Wyss²⁾, Tina Raselli²⁾, Vuc Cerovic³⁾, Andreas W. Sailer⁴⁾, Niklas Krupka¹⁾, Florian Ruiz⁵⁾, Caroline Pot⁵⁾, Oliver Pabst³⁾

- 1) Gastroenterology, University Hospital of Visceral Surgery and Medicine, Inselspital Bern and Bern University, Switzerland
- 2) Department of Gastroenterology and Hepatology, University Hospital Zurich, University of Zurich, Switzerland
- 3) Institute of Molecular Medicine, RWTH Aachen University, 52074 Aachen, Germany
- 4) Disease Area X, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland
- 5) Laboratories of Neuroimmunology, Neuroscience Research Center and Division of Neurology, Department of Clinical Neuroscience, Lausanne University Hospital and University of Lausanne, Switzerland.

Running title: GPR183 in intestinal inflammation

Key words: GPR183, EBI2, UBAC2, oxysterols, inflammatory bowel diseases, innate lymphoid cells, solitary intestinal lymphoid tissue, colitis

Corresponding author:

Benjamin Misselwitz, Gastroenterology, University Hospital of Visceral Surgery and Medicine, Inselspital Bern and Bern University, Freiburgstr. 18, 3010 Bern, Switzerland
benjamin.misselwitz@insel.ch

Disclosures:

- BM has served at an advisory board for Gilead and Novigenix. He has received speaking fees from Vifor, MSD and Takeda and traveling fees from Vifor, Novartis, Gilead, MSD and Takeda. BM has received a research grant from MSD unrelated to this work.
- AW is currently an Abbvie employee.
- TR has been a Takeda employee and is currently employed by Gilead.
- AWS is a Novartis employee and holds stocks and stock options in this company.
- CP has participated in advisory boards for Biogen, Celgene, Merck, Novartis and Roche unrelated to this work
- NK, VC, FR and OP have nothing to disclose

Funding statement: The authors did not receive funding for this study. This work was supported by grants from the Swiss National Science Foundation to BM (grant No. 32473B_156525). O.P. was supported by the German Research Foundation (DFG) Project-ID 403224013 – SFB 1382 (B06)

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/bph.15311

Author's contribution: BM did the literature research and prepared the figures. BM and OP wrote the paper. AWS, TR, AS, NK, FR, CP, VC and OP contributed to the interpretation of data and critically revised the manuscript and all figures for important intellectual content. All authors read and approved the final version of the manuscript. BM is the guarantor of this article.

Abstract

Immune cell trafficking is an important mechanism for the pathogenesis of inflammatory bowel disease (IBD). The G-protein-coupled receptor 183 (GPR183, also called EBI2) and its ligands, dihydroxylated oxysterols can mediate positioning of immune cells including innate lymphoid cells (ILCs). *GPR183* has been mapped to an IBD risk locus; however, another gene, *UBAC2*, is encoded on the reverse strand and associated with Behçet's disease and the role of GPR183 as a genetic risk factor requires validation.

GPR183 and production of its oxysterol ligands are upregulated in human IBD and murine colitis. *Gpr183* inactivation reduced severity of colitis in ILC3-dependent colitis and in IL-10 colitis but not in dextran sodium sulphate colitis. Irrespectively, *Gpr183* knockout strongly reduced accumulation of intestinal lymphoid tissue in health and all colitis models.

In conclusion, genetic, translational and experimental studies implicate GPR183 in IBD pathogenesis and GPR183-dependent cell migration might be a therapeutic drug target for IBD.

List of abbreviations

CCR7	C-C chemokine receptor type 7
CD	Crohn's disease
CH25H	cholesterol 25-hydroxylase
CLPs	colonic patches
CPs	cryptopatches
cSILT	colonic solitary intestinal lymphoid tissue
CXCL8	C-X-C motif chemokine ligand 8
CXCR5	C-X-C chemokine receptor type 5
CYP7B1	cytochrome P450 family 7 subfamily member B1
DCs	dendritic cells
DSS	dextran sodium sulphate
EBI2	Epstein-Barr virus-induced G-protein-coupled receptor 2 (in this review referred to as GPR183)
EIM	extraintestinal manifestations (of IBD)
GM-CSF	granulocyte macrophage colony-stimulating factor
GPR183	G-protein coupled receptor 183 (also called EBI2)
GWAS	genome wide association study
HSD3B7	hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7
IBD	inflammatory bowel diseases
ICAM-1	intercellular adhesion molecule-1
ICOS	inducible T cell co-stimulator
IL	interleukin
ILCs	innate lymphoid cells
ILFs	isolated lymphoid follicles
LPS	lipopolysaccharide
LTi	lymphoid tissue inducer cells
LTo	lymphoid tissue organizing cells
LT	lymphotoxin
LXR	liver X receptor
MAdCAM-1	mucosal addressin cell adhesion molecule-1
MLN	mesenteric lymph nodes
MS	multiple sclerosis
NASH	non-alcoholic steatohepatitis
NFκB	nuclear factor κB
OR	odds ratio
PML	progressive multifocal leukoencephalopathy
PPs	Peyers' patches
RAG1	recombination activating gene
RORγt	retinoic acid related orphan receptor gamma-t
S1PR	sphingosine-1-phosphate receptor
S1P	sphingosine-1-phosphate
SILT	solitary intestinal lymphoid tissue
SNP	single nucleotide polymorphism
TLR	toll like receptor
TLT	tertiary lymphoid tissue
TNBS	trinitrobenzene sulfonic acid
TNF	tumour necrosis factor
TRUC	<i>Tbx21</i> ^{-/-} <i>Rag2</i> ^{-/-} ulcerative colitis

UBAC2	ubiquitin-associated domain-containing gene 2
UC	ulcerative colitis
VCAM-1	vascular cell adhesion molecule-1
7 α ,25-diHC	7 α ,25-dihydroxycholesterol
25-HC	25-hydroxycholesterol

Introduction

In its early days, the field of immune cell migration was dominated by studies on classical adhesion molecules and the chemokine-chemokine receptor system. The study of these systems had opened up exciting therapeutic opportunities in the clinic. However, more recently, additional signals that finely control the movement of distinct immune subsets and their positioning in specific tissues have been identified. Excitingly, these pathways include small molecule metabolites which are well characterised in other systems and link effects of diet, metabolism and the microbiota. Here we focus on one of these systems, the G-protein-coupled receptor 183 (*GPR183*^{*}), also known as Epstein-Barr virus-induced G-protein-coupled receptor 2 (*EBI2*) and its cholesterol-derived ligands. We will discuss genetic information, observations in IBD patients and experimental studies implicating *GPR183* in IBD pathogenesis and morphogenesis of the intestinal immune system.

Role of *GPR183* in the migration and activation of immune cells

7 α ,25-diHC is the main ligand of the oxysterol receptor *GPR183*

GPR183/EBI2 was discovered in 1993 as an Epstein Barr virus-induced orphan receptor in Burkitt lymphoma cell lines (8). *GPR183* ligands remained unknown until 2011, when two landmark publications identified dehydroxylated oxysterols as *GPR183* ligands (9, 10). Oxysterols arise from oxidation of cholesterol. 7 α ,25-dihydroxycholesterol (7 α ,25-diHC) has the strongest affinity to *GPR183*, 7 α ,27-diHC shows second highest affinity whereas other oxysterols (monohydroxylated oxysterols 25-HC and 7 α -HC) show substantially lower activity (9, 10). Synthesis of the *GPR183* ligand 7 α ,25-diHC requires two hydroxylation steps (Figure 1) at position 25 by the enzyme cholesterol 25-hydroxylase (CH25H) and at position 7 α , by cytochrome P450 family 7 subfamily member B1 (CYP7B1). Degradation of 7 α ,25-diHC is catalysed by the enzyme hydroxy-delta-5-steroid dehydrogenase, 3 beta- and steroid delta-isomerase 7 (HSD3B7) (9, 10).

* In this article we follow the drug/ molecular target nomenclature of the Concise guide to Pharmacology 7.

Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. British journal of pharmacology. 2013;170(8):1459-581.. Further, nomenclature of proteins and genes follow international conventions: Proteins will be written non-italic (*GPR183/ Gpr183*), genes in italic (*GPR183/ Gpr183*). Human genes and proteins will be capitalized (*GPR183/ GPR183*), for mouse proteins genes and proteins only the first letter will be capitalized (*Gpr183/ Gpr183*). If we refer to the gene/ protein independent from the species, the capitalized form will be used (*GPR183/ GPR183*).

GPR183 function and its dependence on an oxysterol gradient

GPR183 is expressed on B cells, T cells, dendritic cells (DCs), macrophages and innate lymphoid cells (ILCs) (3, 5, 9-13). In peripheral blood mononuclear cells, highest levels of GPR183 are observed on memory lymphocytes, in particular B and CD4⁺ T cells but to a lesser extent on CD8⁺ T cells (2, 14). Binding of oxysterols to GPR183 leads to the release of intracellular calcium (9), suppression of cAMP (10) and internalization of GPR183 (10). However, the most important consequence of GPR183 activation is migration of GPR183-expressing cells towards higher 7 α ,25-diHC concentrations (3, 5, 9-13, 15).

In secondary lymphatic organs, enzymes for production of 7 α ,25-diHC (i.e. *Ch25h* and *Cyp7b1*) are expressed by the same and/or neighbouring cells while the enzyme for 7 α ,25-diHC degradation (*Hsd3b7*) has a divergent expression pattern (9, 10, 13, 16). This suggests that spatial differences in the synthesis and degradation of 7 α ,25-diHC may result in gradients of oxysterols in lymphoid organs. In agreement with this hypothesis, knockouts of all 7 α ,25-diHC-producing and -degrading enzymes (i.e. *Ch25h*, *Cyp7b1* and *Hsd3b7*) recapitulate important aspects of the phenotype of *Gpr183* deficiency with respect to B and T cell positioning (9, 10, 13, 16). While it is clear that the spatial organization of the enzymatic machinery regulating 7 α ,25-diHC concentrations in the tissue is indeed important for GPR183 function (9, 10, 13, 16), the postulated 7 α ,25-diHC gradient has not been visualized yet.

GPR183-dependent positioning of DCs, T and B cells

For any given antigen only few naïve B and T lymphocytes expressing a cognate antigen receptor exist. Due to this large search space, the probability that a given lymphocyte would encounter a specific antigen by chance is very low. Consequently, the generation and coordination of adaptive immune responses rely on cell migration and proper positioning of the interacting cell types. Sophisticated anatomical structures and mechanisms of cell migration have evolved to increase the likelihood of productive cell-cell encounters and enable the efficient generation of adaptive immune responses.

The principal cell types to initiate adaptive immunity are DCs. DCs take up antigens, process them and transport them to specific sites where they encounter and activate lymphocytes. Thereby, DC migration, proper positioning of DCs and lymphocytes within immune compartments and the anatomical organization of the immune system increase the probability of antigen-presenting DCs to encounter cognate lymphocytes and hence the efficacy of adaptive immunity. Two main subsets of conventional DCs (cDCs) have been described. Broadly, the cDC1 subset plays a key role in CD8 T cell responses whereas the cDC2 subset preferentially interacts with CD4 T cells (17, 18). While upon toll-like receptor (TLR) stimulation, GPR183 expression is upregulated on cDC2s, cDC1s don't seem to express GPR183 (19). GPR183 contributes at various levels to the coordination of cell-cell encounters by modulating the migration and positioning of DCs, T cells and B cells.

GPR183 supports localization of cDC2s at the bridging channel in the spleen and the periphery of lymph node T cell zones, both of which are locations where antigens accumulate and antigen uptake and presentation to T cells may occur (11, 12). Additionally, GPR183 promotes

migration of lymphocytes to the interface between lymph node follicles and the T cell zone, aiding contact with DCs (13). These contacts facilitate differentiation of activated T cells to follicular helper T cells by inducible T cell co-stimulator (ICOS) – ICOS-L interactions and DC-mediated quenching of CD25 signalling (13).

GPR183 specifically facilitates co-localization of cDC2s with CD4 T-helper cells in the peripheral T cell zone as well as antigen-dependent CD4 T cell activation and expansion. In mice, Gpr183 was required for CD4 T cell-dependent protection against helminths and successful plasmodium vaccination (20).

For the activation of B cells in secondary lymphoid organs, GPR183 synergizes with the C-C chemokine receptor type 7 (CCR7) to position B cells at the B–T zone interphase (Figure 3). After having received T cell help, B cells downregulate CCR7 and move to interfollicular and outer follicle regions (9, 10, 16, 21-23). Importantly, vaccination-induced plasma IgG1 responses were reduced in *Gpr183* knockout mice as compared to wild type animals (9). Thus, GPR183 is important for rapid and efficient B cell activation.

GPR183-dependent migration of ILCs in the intestine

Besides supporting the migration of lymphocytes and DCs, GPR183 coordinates the migration of innate lymphoid cells (ILCs). ILCs are innate counterparts of T lymphocytes. Like conventional T cells, ILCs are potent producers of cytokines and are derived from the same common lymphoid progenitor. However, unlike T cells, ILCs lack specific T cell receptors (24-28). ILC1 mirror the functionality of Th1 cells and respond to intracellular pathogens, ILC2s secrete cytokines, which play an important role in anti-parasite and allergic responses and ILC3, like their Th17 counterparts, can participate in defence against extracellular microbes. Since ILCs do not require clonal expansion for their function, they are able to respond without delay to appropriate signals.

In the intestinal mucosa, ILC3s are the dominant type of ILCs and contribute to immunity and barrier integrity (29). ILC3s are characterized by expression of transcription factor retinoic acid related orphan receptor gamma-t (ROR γ t). ILC3s contain commensal bacteria (30) and support defence against enteropathogens (27, 29). Interleukin (IL)-22 is a key cytokine produced by ILC3s that stimulates secretion of antibacterial peptides (31) and also contributes to antiviral defence (32).

Gpr183 is expressed at higher levels on ILC3s in the intestinal lamina propria (3, 5) compared to blood (2) and ILC3s have been shown to migrate towards a $7\alpha,25$ -diHC gradient (5). GPR183 can promote accumulation of ILC3s in the intestine. In experiments with mixed bone marrow chimeras, Gpr183-expressing ILC3 cells clustered in solitary intestinal lymphoid tissue (SILT) of colonic and small intestinal tissue (3), while *Gpr183*^{-/-} cells accumulated in the mesenteric lymph nodes (5).

Gpr183 expression on ILC3s mediates protection against enteric bacterial infections and *Gpr183* deficiency resulted in more severe inflammation in the model of *Citrobacter rodentium* induced colitis. In line with a role of ILCs in this phenotype, *Rag1*^{-/-} *Gpr183*^{-/-} mice had lower

numbers of ILC3 and lower numbers of IL-22 producing ILC3 in the small intestine and in the colon (5).

Fine-tuning of oxysterol gradients

As described above, the generation of the high-affinity GPR183 ligand $7\alpha,25$ -diHC requires the sequential activity of *CH25H* and *CYP7B1*. However, *Ch25h* knockout mice only partially replicate the phenotype of *Gpr183* deficiency (2, 3, 19). Similarly, *Ch25h* and *Cyp7b1* knockouts differ with respect to their effects on DC positioning. These observations suggest a more complex machinery producing and degrading GPR183 ligands. Indeed, the enzyme *Cyp27a1* with 27-hydroxylating activity is able to generate the alternative GPR183 ligand $7\alpha,27$ -diHC (19). $7\alpha,27$ -diHC basically recapitulates $7\alpha,25$ -diHC signalling via GPR183, even though 10-fold higher concentrations are required (9, 10, 19) and $7\alpha,27$ -diHC might result in lower Gpr183 desensitization than $7\alpha,25$ -diHC (19). Thus, local $7\alpha,27$ -diHC and $7\alpha,25$ -diHC availability in secondary lymphoid organs might fine-tune GPR183 signalling. Close spatial expression (including co-expression by the same cell) of the enzyme pairs *Ch25h* and *Cyp7b1* or *Cyp27a1* and *Cyp7b1* would favour generation of $7\alpha,25$ -diHC or $7\alpha,27$ -diHC, respectively.

Oxysterol levels can also be regulated by degradation pathways. In the spleen, activation of the cDC1 subset (not expressing *Gpr183*, see above) further influenced positioning of the *Gpr183*-expressing cDC2 subset. cDC1s express the oxysterol-degrading enzyme *Hsd3b7* and the activity of *Hsd3b7* may prevent movement of GPR183 expressing cells into the vicinity of cDC1s by the degradation of oxysterol gradients (19).

So far, oxysterol gradients in tissues cannot be directly visualized. GPR183 ligands are generated via 7α -hydroxylation (*CYP7B1*) and 25-hydroxylation (*CH25H*, *CYP3* and *CYP46A1*) (33) or 27-hydroxylation (*CYP27A1*) activity (19). A more detailed understanding of the GPR183-oxysterol system will require a better definition of the spatio-temporal dynamics of GPR183 ligand generation and degradation.

Direct effects of GPR183 activation on immune cell function

GPR183 is a well-characterized G-protein coupled receptor and many biological effects of GPR183 described so far involve cellular migration and positioning. However, there is mounting evidence suggesting additional intracellular effects of GPR183. Interestingly, GPR183 has been discovered in an siRNA screen as a host factor for *Mycobacterium tuberculosis* infection in human macrophages (34). In murine macrophages, overexpression of *Gpr183* promoted intracellular *Mycobacterium tuberculosis* replication while knockdown, mutation or chemical inhibition of *Gpr183* reduced *Mycobacterium tuberculosis* infection (35). *Gpr183* expression and activity was also critical in a tissue culture model of non-alcoholic steatohepatitis (36). Further investigation into the direct effects of GPR183 on effector cells of the immune system would open a new layer of complexity and opportunities for more discoveries.

GPR183 in lymphoid organogenesis

Development of the intestinal immune system

The gut associated lymphoid tissue (GALT), comprising distinct immune compartments such as large encapsulated Peyer's patches (PPs) and isolated intestinal follicular structures, initiates and regulates intestinal immune responses. Recent reports reveal how GPR183 contributes to the organization of intestinal lymphoid tissue (2, 3, 5). Before reviewing the role of GPR183 in lymphoid organogenesis, we will briefly summarize key aspects of intestinal lymph organogenesis using the example of Peyer's patches and introduce key features of different GALT structures (see textbox).

Like lymph nodes, PPs are formed during gestation (37). A centre stage in PP organogenesis is taken by hematopoietic lymphoid tissue inducer cells (LTi), which are a subtype of ILC3s. LTi interact with stromal cells known as lymphoid tissue organizing cells (LTo). LTi express lymphotoxin, which binds to lymphotoxin receptor on LTo. Lymphotoxin signalling triggers expression of the chemokine CXCL13 to recruit LTi expressing the chemokine receptor CXCR5 and induces survival and retention of LTi. Clusters of LTi subsequently recruit additional immune cells for formation of mature lymphoid structures (38, 39).

PPs resemble lymph nodes with respect to their typical organization of distinct B and T cell zones (even though at different proportion in PP as compared to lymph nodes). The colonic equivalent to small-intestinal PPs are colonic patches (CLPs). Like PPs, CLPs are formed during gestation. They are located in the muscularis mucosae and 'touch' the intestinal lumen (Figures 3, 4). However, intestinal immune responses are also supported by additional mucosal lymphoid tissues (see below). Some intestinal immune structures, such as PPs, develop independently from inflammation as secondary lymphoid tissues but tertiary lymphoid tissue is also induced in response to chronic inflammation.

Solitary intestinal lymphoid tissue (SILT) is a type of GALT with features between *bona fide* secondary and tertiary lymphoid tissues (Figures 3, 4). SILTs are strictly submucosal structures, close to the intestinal epithelium of the small and large intestine (1). By definition, SILTs never invade or penetrate the muscularis propria. In contrast to lymph nodes, PPs and CLPs, SILTs only appear after birth (37) and development of SILTs requires the presence of LTi (40), lymphotoxin (41) and TLR signalling (1, 42, 43), compare textbox.

Different maturation stages of SILTs can be distinguished. The smallest structures are referred to as cryptopatches (CPs) and comprise mostly LTi and LTo cells, surrounded by DCs. Larger SILTs are known as isolated lymphoid follicles (ILFs). ILFs can reach the size of a PP or CLP and also contain organized B cell follicles. At least in humans, T cell areas and MadCAM-1⁺ vessels for immune cell recruitment were demonstrated (44). Recruited B cells have been shown to undergo T cell-independent class-switch recombination within ILFs. Thus ILFs may be a critical source of T cell-independent IgA (45).

Impact of GPR183 on the development of colonic SILTs (cSILTs)

Several recent studies demonstrated that GPR183 is required for the development of lymphoid tissue in the colon. *Gpr183* knockout mice show a lower number of B-cell positive lymphoid

structures (2, 3, 5). Microscopic examination revealed that colonic SILTs (cSILTs) were mainly affected, while the number of CLPs was constant (2) or only slightly reduced (3). Detailed experiments with conditional *Gpr183* knockouts demonstrated that GPR183 expression by LT α i-like ILC3s is required for generation of colonic SILTs while it is dispensable for the formation of colonic patches (3).

Gpr183 knockout impacted less on the development of SILTs in the small intestine: in one study, the overall number of ILC3s in the small intestinal lamina propria was lower in *Gpr183*^{-/-} and *Ch25h*^{-/-} mice and there were also fewer cryptopatches in the small intestine (5), while in another study, the number of small intestinal SILTs was only marginally reduced (3). Most likely, the GPR183-7 α ,25-diHC axis is also active in the small intestine, mediating recruitment of immune cells. However, B cells seem to be able to compensate for loss of LT α i-like ILC3 function in the small intestine, but not in the colon (3).

Immune cell migration into CPs and ILFs is dependent on Ch25h activity, which is required for synthesis of the GPR183 ligand 7 α ,25-diHC. More detailed evaluations revealed expression of the 7 α ,25-diHC producing enzymes Cyp7b1 and Ch25h in CD34⁺podoplanin⁺ fibroblasts within ILFs, while CD34⁺podoplanin⁺ fibroblasts outside ILFs produced the 7 α ,25-diHC degrading enzyme Hsd3b7 (3). This differential enzyme expression pattern suggests existence of a 7 α ,25-diHC gradient around SILTs which would mediate the recruitment of Gpr183 expressing ILC3s, B cells and DCs into SILTs.

Despite these profound alterations of the GALT of *Gpr183* knockout mice, their intestinal immune system remained intact and no further impairment of functionality could be detected in the absence of environmental challenges: The number of mesenteric lymph nodes and the total number of B cells in the colon was normal with normal faecal IgA levels (2, 3). Furthermore, no differences in microbiota composition were found in *Gpr183* deficient mice and the fraction of IgA coated bacteria remained normal (2). Interestingly, in colonic ILC3s, IL-22 production was reduced upon *Gpr183* knockout (3).

GPR183 in intestinal inflammation

The *GPR183* locus is a risk locus for inflammatory bowel diseases

Inflammatory bowel diseases are chronic inflammatory conditions and comprise the major subgroups Crohn's disease (CD) and ulcerative colitis (UC). While in UC disease activity is restricted to the colon with strongest inflammatory activity in the rectum, CD can affect the whole intestinal tract. The pathogenesis of IBD is unknown but genetic and environmental risk factors have been identified (46, 47).

Genome wide association studies (GWAS) have linked the GPR183-oxysterol system to IBD. GWAS identified >240 genetic regions and most identified genes increased the risk for both, UC and CD (48-51). One IBD risk gene maps to the genetic region encoding GPR183. The single nucleotide polymorphism (SNP) rs9557195 on chromosome 13 within an intron of *GPR183* (Figure 5) is associated with CD (odds ratio (OR) of 1.12; 95% CI: 1.08-1.16) and UC (OR 1.1; 95% CI 1.06-1.15) (48). Association of SNP rs9557195 with both UC and CD, suggests a potentially more general role of the *GPR183* locus for inflammatory mechanisms

and/or organization of the gastrointestinal immune system. Very recent data from our group indicate increased GPR183 expression on the surface of immune cells in individuals with the CC-allele of rs9557195 [F. Ruiz, C. Pot, B. Misselwitz manuscript submitted], providing the first experimental confirmation of these genetic data in human samples.

The *UBAC2* gene is a second gene at the *GPR183* locus and associated with Behçet's disease

The architecture of the human *GPR183* gene locus is complex. The ubiquitin-associated domain-containing gene 2 (*UBAC2*) is located on the complementary DNA strand and contains several intron and exon regions overlapping with *GPR183* (Figure 5). *GPR18*, another G-protein coupled receptor, also overlaps with *UBAC2*. Several studies associated SNPs within the *UBAC2* gene with the risk for Behçet's disease (52-54). Behçet's disease is a rare condition but more frequently occurring along the ancient silk road from Eastern Asia to Mediterranean with most cases in Turkey (55).

Behçet's disease is a small vessel vasculitis, diagnosed upon occurrence of recurrent bipolar (oral and genital) aphthae and additional systemic manifestations with involvement of eyes, skin (erythema nodosum and pyoderma gangraenosum), the nervous system and joints. Gastrointestinal involvement occurs in 10-15% of patients with abdominal pain, diarrhoea and intestinal ulcerations frequently in the ileocecal region (56, 57).

Manifestations of Behçet's disease may thus overlap with intestinal and extraintestinal manifestations (EIM) of CD, making a correct disease diagnosis challenging (56). Further, IBD and Behçet's disease respond to similar medical treatments (57) and have genetic overlap (58). It is therefore possible that Behçet's disease mutations contribute to the risk of EIM in IBD but the clinical relevance of the overlap of IBD with Behçet's disease remains unknown.

UBAC2 expression was increased in peripheral blood mononuclear cells in patients carrying risk alleles of two Behçet's disease-associated SNPs (rs7999348 and rs3825427, Figure 5) (52, 53). *UBAC2* is part of an endoplasmic reticulum (ER) membrane protein complex, which can inhibit wnt/ β -catenin signalling, and defects of other proteins in this complex result in severe lymphocyte dysfunction (59). In another study, *UBAC2* restricted trafficking of ubiquitin-like-domain-containing protein 8 (also called FAF2) from the ER to lipid droplets (60). Besides *UBAC2*, other ubiquitination-related genes (*UBASH3B*, *SUMO4*) have also been associated with Behçet's disease, suggesting a crucial role of ubiquitination in the pathogenesis of this condition (52, 53, 61). However, it remains unclear how *UBAC2* can contribute to organ inflammation.

The IBD-associated SNP rs9557195 is located within introns of both genes, *GPR183* and *UBAC2*, and it remains unclear how much each of those genes contributes to IBD risk. rs9557195 might act via *GPR183* since it is associated with the risk for both CD and UC, while Behçet's disease mainly overlaps with CD. Further, our unpublished observations show increased *GPR183* expression in individuals with the rs9557195-CC allele (see above).

However, in CD patients resistant to anti-tumour necrosis factor (TNF) treatment, an expression quantitative trait loci (eQTL) study identified elevated *UBAC2* levels in individuals

with the rs9557195-TT genotype in peripheral blood and the intestine (62). Further, rs3742130, another SNP within UBAC2/GPR18 was associated with anti-TNF non-responsiveness (63), raising the possibility of involvement of UBAC2 in IBD as well. However, none of the studies of either GPR183 or UBAC2, rigorously excluded the effects of the other gene, hence a role of both genes in IBD is possible.

Murine models of IBD suggest proinflammatory effects of GPR183

Experimental observations indicate an important role of GPR183 in inflammation and pathogenesis of colitis. In the anti-CD40 colitis model, colon inflammation is induced by injection of the anti-CD40 antibody into *Rag1*^{-/-} mice. Reduced overall inflammation and fewer inflammatory foci containing Gpr183 expressing ILC3s and myeloid cells were observed in *Rag1*^{-/-} *Gpr183*^{-/-} animals, compared to animals with functional Gpr183 (3). *Gpr183* knockout also reduced granulocyte macrophage colony-stimulating factor (GM-CSF) production (3), which had been suggested as a key pro-inflammatory activity of ILC3s in innate colitis.

Similarly, GPR183 confers pro-inflammatory effects in the IL-10 model of chronic colitis: *Gpr183*^{-/-} *Il-10*^{-/-} animals had less severe inflammation compared to *Il-10*^{-/-} controls (2). Notably, the IL-10 colitis model shows at least some relevance for human IBD, since *IL-10* mutations have been linked to the human disease (64). Interestingly, in IL-10 colitis, the *Gpr183* phenotype was restricted to male animals (2). The reason for this sex-difference is unclear but related observations have also been reported in other colitis models (65). Further, in humans, polymorphisms in the IL-10 gene can also act in a gender specific manner (66) and *CYP7B1*, one of the enzymes necessary for 7 α ,25-diHC production, is a male dominant gene (67). In any case, mechanistic effects how Gpr183 increased colon inflammation in Il-10 colitis remain unclear.

In contrast, in acute and chronic chemical (dextrane sodium sulphate: DSS) colitis, knockout of *Gpr183* did not affect intestinal inflammation (2). This suggests that GPR183 effects on intestinal inflammation depend on the particular system and mode of pathogenesis.

Intestinal inflammation affects balancing of the GPR183–oxysterol system

GPR183 mRNA levels as well as mRNA of enzymes producing 7 α ,25-diHC (*CH25H*, *CYP7B1*) are upregulated in biopsies of UC patients with active disease compared to patients in remission or healthy controls (2). Expression levels correlated with disease activity and established inflammatory markers including TNF or C-X-C motif chemokine ligand 8 (CXCL8) expression (2, 3). *GPR183* expression was also induced by lipopolysaccharide (LPS) on human macrophages (10, 68, 69), with possible repression in the murine system (69, 70), possibly related to ligand-induced GPR183 downregulation.

In murine colitis, activation of the GPR183-7 α ,25-diHC axis was also observed and confirmed by oxysterol measurements. Most experiments were done in the acute and chronic DSS colitis model, which relies on chemical destruction of the intestinal barrier and innate immune activation. Measurements in acute DSS colitis confirmed increased expression of *Gpr183*, *Cyp7b1* and *Ch25h* in the gut (2, 71) and higher levels of the oxysterols 4 β -HC, 25-HC and 7 α ,25-diHC in the gut mucosa (2, 72, 73). Similar changes, correlating with colitis severity,

were observed in chronic DSS colitis (72). In one study, 7 α ,25-diHC was elevated in colon and stool and usage of 7 α ,25-diHC as a biomarker was suggested for IBD (73). Trinitrobenzene sulfonic acid (TNBS) induced colitis resulted in increased levels of 4 β -HC, 25-HC but not 7 α ,25-diHC (72). Increased *Ch25h* expression and production of an activity, stimulating Gpr183 dependent cell migration was also observed in innate anti-CD40 colitis (3).

While an increase in 25-HC and 7 α ,25-diHC was repeatedly observed, expression levels of *Cyp27a1* (responsible for production of 27-HC and the alternative GPR183 ligand 7 α ,27-diHC) were not affected in IL-10, DSS or TNBS colitis (2, 72), while *Hsd3b7* levels (responsible for degradation of most oxysterols) were normal or even decreased (2, 72).

Upregulation of oxysterol synthesis and increased oxysterol concentrations were also observed in human and murine models of non-alcoholic steatohepatitis (NASH) but knockouts of *Gpr183*, *Cyp7b1* or *Ch25h* did not affect severity of NASH (74).

In summary, there is strong and consistent evidence for increased expression of the enzymes synthesizing the GPR183 ligand 7 α ,25-diHC in human samples and four different mouse models of colitis and enzyme levels correlate with severity of inflammation. In biochemical analyses, higher intestinal 7 α ,25-diHC levels were observed in murine tissue upon inflammation in most models (2, 3, 72, 73). However, levels of other oxysterols varied to a higher degree. Most likely, the degree of systemic and local inflammation differed according to the mouse models used. Further, mass spectrometry determinations of di-hydroxylated oxysterols can be challenging, likely explaining most discrepancies.

Non-GPR183 mediated effects of oxysterols in intestinal inflammation

While pro-inflammatory effects of GPR183 in inflammation are increasingly recognized, it has long been established that oxysterols are immune-modulatory molecules with broad activities (75) (Table 1).

The induction of *CH25H* is a general feature in inflammation. Several TLR agonists increased *CH25H* mRNA levels and increased 25-HC production in human and murine macrophages (10, 68, 76-80). In line with these results, in human healthy volunteers, serum 25-HC concentration increased upon LPS injection (77).

25-HC also has broad immune-modulatory effects. It is a powerful inhibitor of human viruses (78, 79) and was very recently identified as an efficient antibacterial molecule in *Listeria monocytogenes* and *Shigella flexneri* infection (81). Antibacterial effects are mediated by redistribution of membrane cholesterol and reduction of accessible membrane cholesterol (81). 25-HC also inhibits inflammasome assembly, caspase activation and IL-1 and IL-18 production in macrophages (82) while IL-1 can in turn induce Th-17 differentiation (83).

Therefore, not all effects of oxysterols in intestinal inflammation are mediated by GPR183 (Table 1) and the oxysterol receptors liver X receptor (LXR)- α and LXR- β have a role in colitis. LXR- α and LXR- β are activated by oxysterols including 25-HC and 27-HC (84). More severe DSS colitis was observed upon knockdown of *Lxr- β* and/ or *Lxr- α* while the LXR agonist GW3965 improved clinical course of DSS colitis (85). Thereby, *Lxr- β* and *Lxr-*

α reduced activation of CD11b⁺ immune cells, while Lxr- β in addition downregulated secretion of inflammatory mediators in colonic epithelial cells (85). Recent experiments have also associated *Ch25h* with intestinal fibrosis in two animal models (71).

Moreover, dihydroxylated oxysterols such as $7\alpha,27$ -diHC and $7\beta,27$ diHC are agonists of ROR γ t and regulate Th17 cell differentiation (86). Since Th17 cells have been shown to be of relevance in IBD pathogenesis (87) oxysterol mediated ROR γ t stimulation is likely relevant in IBD. Distinguishing GPR183-mediated effects of oxysterols from effects on LXR, ROR γ t and pleiotropic oxysterol effects (see below) remains a challenge.

GPR183-dependent accumulation of lymphoid tissue in chronic colitis

Whereas colonic patches are clearly distinct in their anatomical localization and structure, cSILT and TLT in the colon cannot easily be distinguished by histology and foremost differ in their developmental requirements. Thus, lymphoid tissue observed in the inflamed colon might represent true TLT and/or more mature and/or hypertrophic cSILT.

Build-up of colonic lymphoid tissue seems to require a prolonged inflammatory stimulus: no changes of cSILT/TLT numbers were seen in acute DSS colitis, while in chronic DSS colitis a pronounced increase of cSILTs/TLTs could be observed (88). Accumulated lymphoid tissue comprises B cells with germinal centres, DCs and CD4 T cells but no T cell areas. High endothelial venules are frequently observed around inflammation-induced TLTs, which would facilitate further recruitment of immune cells (89).

Accumulation of TLTs in chronic inflammation is dependent on GPR183: in chronic chemical (DSS) colitis, in *Gpr183*^{-/-} animals, low cSILT/TLT numbers were seen at baseline without any inflammation dependent increase, despite similar levels of inflammation in *Gpr183*^{-/-} and wildtype animals (2). Interestingly, the increase in cSILT/TLT was only partially dependent on *Ch25h*, suggesting activity of either Cyp27a1 (for production of $7\alpha,27$ -diHC) or activity of other enzymes with 25-hydroxylation activity (see above).

Inflammation in chronic IL-10 colitis also increased the number of cSILTs/TLTs with a strong correlation of the number of lymphoid structures and the level of inflammation (2). Upon *Gpr183* knockout, an overall lower number of SILTs was observed even in animals with similar levels of inflammation (2). In innate anti-CD40 colitis, *Gpr183* was also required for an inflammatory migratory response and induction of lymphoid tissue during inflammation (3). Therefore, there seems to be a universal requirement for Gpr183 for the induction of inflammatory lymphoid tissue, independent from the way colon inflammation was induced.

For induction of SILTs in inflammation, B cells might be able to take on the function of LTis. In chronic DSS colitis, accumulation of lymphoid tissue required lymphotoxin but not ROR γ t and the authors demonstrated a critical function of B cells for induction of lymphoid tissue upon ROR γ t knockout (88). Since GPR183 is expressed on ILCs and B cells, GPR183 might support both, the classical LTi (ILC3)-dependent induction of cSILTs as well as the alternative B cell dependent pathway, described above. However, this still needs to be confirmed directly.

A recent study indicated that ILC3s were predominantly localized in CPs but ILC3 motility increased after induction of anti-CD40 colitis resulting in preferential ILC3s egress from CPs

(90). It is unclear whether this change of motility depends on GPR183 and whether it is related to inflammation and/ or accumulation of lymphoid tissue.

The detailed function of the accumulated colonic lymphoid tissue in chronic colitis is unclear. It is unknown whether they have more pro-inflammatory or anti-inflammatory properties in the context of infection or IBD and discrepant results have been described in different models (91). While in some murine studies, colitis was dependent on accumulated cSILT/TLT (3, 88, 92, 93), in other studies no correlation between cSILTs/TLTs and chronic inflammation was observed (2, 94). Accumulation of lymphoid follicles and lymphangitis are also a hallmark of human small intestinal Crohn's disease but pathogenesis and implications for management of these findings are insufficiently understood (91, 95, 96).

In summary, recruitment of immune cells into the colon upon chronic inflammation remains a complex process (Table 1) and CXCL13, IL-22, IL-23, lymphotoxin, the microbiota (6, 88, 92) and possibly also the CXCR5-CXCL13 axis (97) have been implicated. Recent data also indicate a role of GPR183 in this process (2). Further studies of GPR183 in intestinal inflammation might also reveal relevance and functional impact of lymphoid tissue accumulation in colitis.

The GPR183-oxysterol axis as a potential drug target for IBD

Targeting immune cell migration

Inhibition of immune cell migration is a well-established therapy principle in IBD and other inflammatory conditions. Current approaches include integrin inhibition, sphingosin-1-phosphate receptor (S1PR) modulation and chemokine receptor blockage. GPR183 modulation might constitute a new therapeutic approach, non-redundant with established therapies and with potentially unique effects.

Integrin inhibitors have been the first approved drugs to block cellular migration. Homing of immune cells into the gut is mediated by integrin- α 4 β 7. Natalizumab (blocking the integrin- α 4 subunit) and vedolizumab (blocking integrin- α 4 β 7) are of therapeutic value in IBD (98-101). Natalizumab (102) (but not the gut specific vedolizumab (103)) is associated with the risk of the opportunistic infection progressive multifocal leukoencephalopathy (PML). Therefore, natalizumab is rarely if ever used in IBD. However, in patients with multiple sclerosis (MS) under natalizumab treatment, GPR183 expression and activity is increased on the surface of CD4 memory T cells compared to before treatment (14), suggesting high GPR183 expression in immune cells destined to target inflamed tissues such as the brain in MS and/ or the intestine (104).

S1PR mediate exit of lymphocytes from secondary lymphoid organs. Lymphocytes follow a sphingosine-1-phosphate (S1P) gradient with higher S1P concentrations in blood. S1PR blockade results in functional inactivation of lymphocytes by trapping them within lymphoid organs (105). Ozanimod (blocking S1PR1 and S1PR5) showed some activity in UC patients. In line with entrapment of lymphocytes as the mode of action for ozanimod, peripheral lymphocyte counts decreased by almost 50% (106, 107).

Chemokine receptors CCR6, CCR9 and CXCR3 and its ligands mediate recruitment of immune cells into the gut in health and/ or inflammation; however, clinical tests of blocking these chemokine receptors in IBD remained disappointing (108-112), most likely due to redundant migratory signals for immune cell recruitment into the inflamed gut.

Effects of GPR183 inhibition would likely differ from inhibition of integrins, S1PR and chemokine receptors. In animal experiments, GPR183 knockout did not reduce the overall number of intestinal lymphocytes, but affected immune cell distribution in the intestine with reduction of SILTs (2, 3) and entrapment of lymphocytes in mesenteric lymph nodes (5). In inflammation, GPR183 mediated accumulation of tertiary lymphoid follicles in the mucosa with pro-inflammatory effects in some but not all animal models (2, 3). Since our understanding of the function of SILTs in health and inflammation is limited, effects of GPR183 inhibition in human IBD is not foreseeable, but the opportunity of a new drug target in intestinal inflammation is highly welcome.

Blocking of the GPR183–oxysterol axis

A chemical inhibitor which prevents binding of $7\alpha,25$ -diHC to GPR183 and hence $7\alpha,25$ -diHC dependent migration of immune cells can be used as an GPR183 blocker (113, 114). In mice, this inhibitor replicated DC positioning phenotypes of the *Gpr183* knockout (19), but has not been tested in murine colitis.

Targeting oxysterol synthesis, such as blocking Cyp7b1 by clotrimazole (10), could be used as additional therapeutic strategy. However, to the best of our knowledge, knockouts of *Cyp7b1*, *Ch25h* or *Cyp27a1* have not been tested in *Gpr183* dependent colitis models so the therapeutic potential for IBD remains unexplored. Conversely, in mice, application of 25-HC drastically changed oxysterol levels (including $7\alpha,25$ -diHC) but did not alter severity of DSS colitis (72).

Conclusion and outlook

The immune system is organized in a multi-layered, fractal-like manner. GPR183 is a key factor involved in the spatial organization of the immune system and in particular the development of lymphoid tissues in the intestine. Human genetics and animal experiments have suggested a role of GPR183 in colitis. However, for now, we are still far from understanding the function of GPR183 in intestinal inflammation. Of note, it remains unclear whether the effects of the IBD polymorphism rs9557195 are mediated via GPR183 or UBAC2. Furthermore, the mechanisms by which GPR183 promotes intestinal inflammation in some, but not all animal models has not been clarified. Moreover, the impact of GPR183 mediated accumulation of lymphoid tissue in colitis, and its impact on inflammation and healing are unclear. Finally, broad immune-modulatory effects of oxysterols and possible direct effects of GPR183 on immune cells have been described and need further study to be distinguished from the effects of GPR183 on cell motility and migration. Notably, downstream effects of GPR183 inhibition, disrupting intestinal immune cell distribution may be unique and different from all other cellular migration inhibitors and warrant further efforts to assess the therapeutic potential for GPR183 inhibition in IBD.

Nomenclature of targets and ligands

Key protein targets and ligands in this article are hyperlinked to the corresponding entries in <http://www.guidetopharmacology.org>, the common portal for data from the IUHAR/BPS Guide to pharmacology (115), and are permanently archived in the Concise Guide to PHARMACOLOGY 2019/20 (7).

References

1. Baptista AP, Olivier BJ, Goverse G, Greuter M, Knippenberg M, Kusser K, et al. Colonic patch and colonic SILT development are independent and differentially regulated events. *Mucosal Immunol.* 2013;6(3):511-21.
2. Wyss A, Raselli T, Perkins N, Ruiz F, Schmelcz G, Klink G, et al. The EBI2-oxysterol axis promotes the development of intestinal lymphoid structures and colitis. *Mucosal Immunol.* 2019;12(3):733-45.
3. Emgard J, Kammoun H, Garcia-Cassani B, Chesne J, Parigi SM, Jacob JM, et al. Oxysterol Sensing through the Receptor GPR183 Promotes the Lymphoid-Tissue-Inducing Function of Innate Lymphoid Cells and Colonic Inflammation. *Immunity.* 2018;48(1):120-32 e8.
4. Velaga S, Herbrand H, Friedrichsen M, Jiong T, Dorsch M, Hoffmann MW, et al. Chemokine receptor CXCR5 supports solitary intestinal lymphoid tissue formation, B cell homing, and induction of intestinal IgA responses. *J Immunol.* 2009;182(5):2610-9.
5. Chu C, Moriyama S, Li Z, Zhou L, Flamar AL, Klose CSN, et al. Anti-microbial Functions of Group 3 Innate Lymphoid Cells in Gut-Associated Lymphoid Tissues Are Regulated by G-Protein-Coupled Receptor 183. *Cell Rep.* 2018;23(13):3750-8.
6. Olivier BJ, Cailotto C, van der Vliet J, Knippenberg M, Greuter MJ, Hilbers FW, et al. Vagal innervation is required for the formation of tertiary lymphoid tissue in colitis. *Eur J Immunol.* 2016;46(10):2467-80.
7. Alexander SP, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. The Concise Guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. *British journal of pharmacology.* 2013;170(8):1459-581.
8. Birkenbach M, Josefsen K, Yalamanchili R, Lenoir G, Kieff E. Epstein-Barr virus-induced genes: first lymphocyte-specific G protein-coupled peptide receptors. *J Virol.* 1993;67(4):2209-20.
9. Hannedouche S, Zhang J, Yi T, Shen W, Nguyen D, Pereira JP, et al. Oxysterols direct immune cell migration via EBI2. *Nature.* 2011;475(7357):524-7.
10. Liu C, Yang XV, Wu J, Kuei C, Mani NS, Zhang L, et al. Oxysterols direct B-cell migration through EBI2. *Nature.* 2011;475(7357):519-23.
11. Gatto D, Wood K, Caminschi I, Murphy-Durland D, Schofield P, Christ D, et al. The chemotactic receptor EBI2 regulates the homeostasis, localization and immunological function of splenic dendritic cells. *Nat Immunol.* 2013;14(8):876.
12. Yi T, Cyster JG. EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. *Elife.* 2013;2:e00757.
13. Li J, Lu E, Yi T, Cyster JG. EBI2 augments Tfh cell fate by promoting interaction with IL-2-quenching dendritic cells. *Nature.* 2016;533(7601):110-4.

14. Clottu AS, Mathias A, Sailer AW, Schluep M, Seebach JD, Du Pasquier R, et al. EBI2 Expression and Function: Robust in Memory Lymphocytes and Increased by Natalizumab in Multiple Sclerosis. *Cell Rep.* 2017;18(1):213-24.
15. Lu E, Cyster JG. G-protein coupled receptors and ligands that organize humoral immune responses. *Immunol Rev.* 2019;289(1):158-72.
16. Yi T, Wang X, Kelly LM, An J, Xu Y, Sailer AW, et al. Oxysterol gradient generation by lymphoid stromal cells guides activated B cell movement during humoral responses. *Immunity.* 2012;37(3):535-48.
17. Durai V, Murphy KM. Functions of Murine Dendritic Cells. *Immunity.* 2016;45(4):719-36.
18. Joeris T, Muller-Luda K, Agace WW, Mowat AM. Diversity and functions of intestinal mononuclear phagocytes. *Mucosal Immunol.* 2017;10(4):845-64.
19. Lu E, Dang EV, McDonald JG, Cyster JG. Distinct oxysterol requirements for positioning naive and activated dendritic cells in the spleen. *Sci Immunol.* 2017;2(10).
20. Baptista AP, Gola A, Huang Y, Milanez-Almeida P, Torabi-Parizi P, Urban JF, Jr., et al. The Chemoattractant Receptor Ebi2 Drives Intranodal Naive CD4(+) T Cell Peripheralization to Promote Effective Adaptive Immunity. *Immunity.* 2019;50(5):1188-201 e6.
21. Gatto D, Paus D, Basten A, Mackay CR, Brink R. Guidance of B cells by the orphan G protein-coupled receptor EBI2 shapes humoral immune responses. *Immunity.* 2009;31(2):259-69.
22. Kelly LM, Pereira JP, Yi T, Xu Y, Cyster JG. EBI2 guides serial movements of activated B cells and ligand activity is detectable in lymphoid and nonlymphoid tissues. *J Immunol.* 2011;187(6):3026-32.
23. Pereira JP, Kelly LM, Xu Y, Cyster JG. EBI2 mediates B cell segregation between the outer and centre follicle. *Nature.* 2009;460(7259):1122-6.
24. Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, et al. Innate Lymphoid Cells: 10 Years On. *Cell.* 2018;174(5):1054-66.
25. Ebbo M, Crinier A, Vely F, Vivier E. Innate lymphoid cells: major players in inflammatory diseases. *Nat Rev Immunol.* 2017;17(11):665-78.
26. Kotas ME, Locksley RM. Why Innate Lymphoid Cells? *Immunity.* 2018;48(6):1081-90.
27. Panda SK, Colonna M. Innate Lymphoid Cells in Mucosal Immunity. *Front Immunol.* 2019;10:861.
28. Mjosberg J, Spits H. Human innate lymphoid cells. *J Allergy Clin Immunol.* 2016;138(5):1265-76.
29. Pantazi E, Powell N. Group 3 ILCs: Peacekeepers or Troublemakers? What's Your Gut Telling You?! *Front Immunol.* 2019;10:676.
30. Sonnenberg GF, Monticelli LA, Alenghat T, Fung TC, Hutnick NA, Kunisawa J, et al. Innate lymphoid cells promote anatomical containment of lymphoid-resident commensal bacteria. *Science.* 2012;336(6086):1321-5.
31. Zheng Y, Valdez PA, Danilenko DM, Hu Y, Sa SM, Gong Q, et al. Interleukin-22 mediates early host defense against attaching and effacing bacterial pathogens. *Nat Med.* 2008;14(3):282-9.
32. Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, et al. Interferon-lambda and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. *Nat Immunol.* 2015;16(7):698-707.
33. Griffiths WJ, Wang Y. An update on oxysterol biochemistry: New discoveries in lipidomics. *Biochem Biophys Res Commun.* 2018;504(3):617-22.

34. Kumar D, Nath L, Kamal MA, Varshney A, Jain A, Singh S, et al. Genome-wide analysis of the host intracellular network that regulates survival of Mycobacterium tuberculosis. *Cell*. 2010;140(5):731-43.
35. Tang J, Shi Y, Zhan L, Qin C. Downregulation of GPR183 on infection restricts the early infection and intracellular replication of mycobacterium tuberculosis in macrophage. *Microb Pathog*. 2020;145:104234.
36. Huang J, Lee SJ, Kang S, Choi MH, Im DS. 7alpha,25-dihydroxycholesterol protects against liver X receptor-mediated steatosis through GPR183/EBI2 in human and mouse hepatocytes. *J Pharmacol Exp Ther*. 2020.
37. Buettner M, Lochner M. Development and Function of Secondary and Tertiary Lymphoid Organs in the Small Intestine and the Colon. *Front Immunol*. 2016;7:342.
38. Randall TD, Carragher DM, Rangel-Moreno J. Development of secondary lymphoid organs. *Annu Rev Immunol*. 2008;26:627-50.
39. van de Pavert SA, Mebius RE. New insights into the development of lymphoid tissues. *Nat Rev Immunol*. 2010;10(9):664-74.
40. Eberl G, Littman DR. Thymic origin of intestinal alphabeta T cells revealed by fate mapping of RORgammat+ cells. *Science*. 2004;305(5681):248-51.
41. Lorenz RG, Chaplin DD, McDonald KG, McDonough JS, Newberry RD. Isolated lymphoid follicle formation is inducible and dependent upon lymphotoxin-sufficient B lymphocytes, lymphotoxin beta receptor, and TNF receptor I function. *J Immunol*. 2003;170(11):5475-82.
42. Bouskra D, Brezillon C, Berard M, Werts C, Varona R, Boneca IG, et al. Lymphoid tissue genesis induced by commensals through NOD1 regulates intestinal homeostasis. *Nature*. 2008;456(7221):507-10.
43. Pabst O, Herbrand H, Friedrichsen M, Velaga S, Dorsch M, Berhardt G, et al. Adaptation of solitary intestinal lymphoid tissue in response to microbiota and chemokine receptor CCR7 signaling. *J Immunol*. 2006;177(10):6824-32.
44. Fenton TM, Jorgensen PB, Niss K, Rubin SJS, Morbe UM, Riis LB, et al. Immune Profiling of Human Gut-Associated Lymphoid Tissue Identifies a Role for Isolated Lymphoid Follicles in Priming of Region-Specific Immunity. *Immunity*. 2020;52(3):557-70 e6.
45. Tsuji M, Suzuki K, Kitamura H, Maruya M, Kinoshita K, Ivanov, II, et al. Requirement for lymphoid tissue-inducer cells in isolated follicle formation and T cell-independent immunoglobulin A generation in the gut. *Immunity*. 2008;29(2):261-71.
46. Vedamurthy A, Ananthakrishnan AN. Influence of Environmental Factors in the Development and Outcomes of Inflammatory Bowel Disease. *Gastroenterology & hepatology*. 2019;15(2):72-82.
47. Annese V. Genetics and epigenetics of IBD. *Pharmacol Res*. 2020;159:104892.
48. Jostins L, Ripke S, Weersma RK, Duerr RH, McGovern DP, Hui KY, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. *Nature*. 2012;491(7422):119-24.
49. de Lange KM, Moutsianas L, Lee JC, Lamb CA, Luo Y, Kennedy NA, et al. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. *Nat Genet*. 2017;49(2):256-61.
50. Franke A, McGovern DP, Barrett JC, Wang K, Radford-Smith GL, Ahmad T, et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. *Nat Genet*. 2010;42(12):1118-25.

51. McGovern DP, Gardet A, Torkvist L, Goyette P, Essers J, Taylor KD, et al. Genome-wide association identifies multiple ulcerative colitis susceptibility loci. *Nat Genet.* 2010;42(4):332-7.
52. Sawalha AH, Hughes T, Nadig A, Yilmaz V, Aksu K, Keser G, et al. A putative functional variant within the UBAC2 gene is associated with increased risk of Behcet's disease. *Arthritis Rheum.* 2011;63(11):3607-12.
53. Hou S, Shu Q, Jiang Z, Chen Y, Li F, Chen F, et al. Replication study confirms the association between UBAC2 and Behcet's disease in two independent Chinese sets of patients and controls. *Arthritis Res Ther.* 2012;14(2):R70.
54. Yamazoe K, Meguro A, Takeuchi M, Shibuya E, Ohno S, Mizuki N. Comprehensive analysis of the association between UBAC2 polymorphisms and Behcet's disease in a Japanese population. *Sci Rep.* 2017;7(1):742.
55. Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. *Curr Opin Rheumatol.* 2004;16(1):38-42.
56. Valenti S, Gallizzi R, De Vivo D, Romano C. Intestinal Behcet and Crohn's disease: two sides of the same coin. *Pediatr Rheumatol Online J.* 2017;15(1):33.
57. Cheon JH, Kim WH. An update on the diagnosis, treatment, and prognosis of intestinal Behcet's disease. *Curr Opin Rheumatol.* 2015;27(1):24-31.
58. Takeuchi M, Mizuki N, Meguro A, Ombrello MJ, Kirino Y, Satorius C, et al. Dense genotyping of immune-related loci implicates host responses to microbial exposure in Behcet's disease susceptibility. *Nat Genet.* 2017;49(3):438-43.
59. Choi JH, Zhong X, McAlpine W, Liao TC, Zhang D, Fang B, et al. LMBR1L regulates lymphopoiesis through Wnt/beta-catenin signaling. *Science.* 2019;364(6440).
60. Olzmann JA, Richter CM, Kopito RR. Spatial regulation of UBXD8 and p97/VCP controls ATGL-mediated lipid droplet turnover. *Proc Natl Acad Sci U S A.* 2013;110(4):1345-50.
61. Fei Y, Webb R, Cobb BL, Direskeneli H, Saruhan-Direskeneli G, Sawalha AH. Identification of novel genetic susceptibility loci for Behcet's disease using a genome-wide association study. *Arthritis Res Ther.* 2009;11(3):R66.
62. Di Narzo AF, Peters LA, Argmann C, Stojmirovic A, Perrigoue J, Li K, et al. Blood and Intestine eQTLs from an Anti-TNF-Resistant Crohn's Disease Cohort Inform IBD Genetic Association Loci. *Clin Transl Gastroenterol.* 2016;7(6):e177.
63. Burke KE, Khalili H, Garber JJ, Haritunians T, McGovern DPB, Xavier RJ, et al. Genetic Markers Predict Primary Nonresponse and Durable Response to Anti-Tumor Necrosis Factor Therapy in Ulcerative Colitis. *Inflamm Bowel Dis.* 2018;24(8):1840-8.
64. Kotlarz D, Beier R, Murugan D, Diestelhorst J, Jensen O, Boztug K, et al. Loss of interleukin-10 signaling and infantile inflammatory bowel disease: implications for diagnosis and therapy. *Gastroenterology.* 2012;143(2):347-55.
65. Schaubeck M, Clavel T, Calasan J, Lagkouvardos I, Haange SB, Jehmlich N, et al. Dysbiotic gut microbiota causes transmissible Crohn's disease-like ileitis independent of failure in antimicrobial defence. *Gut.* 2016;65(2):225-37.
66. Tedde A, Laura Putignano A, Bagnoli S, Congregati C, Milla M, Sorbi S, et al. Interleukin-10 promoter polymorphisms influence susceptibility to ulcerative colitis in a gender-specific manner. *Scand J Gastroenterol.* 2008;43(6):712-8.
67. Wauthier V, Sugathan A, Meyer RD, Dombkowski AA, Waxman DJ. Intrinsic sex differences in the early growth hormone responsiveness of sex-specific genes in mouse liver. *Mol Endocrinol.* 2010;24(3):667-78.

68. Preuss I, Ludwig MG, Baumgarten B, Bassilana F, Gessier F, Seuwen K, et al. Transcriptional regulation and functional characterization of the oxysterol/EBI2 system in primary human macrophages. *Biochem Biophys Res Commun*. 2014;446(3):663-8.
69. Schroder K, Irvine KM, Taylor MS, Bokil NJ, Le Cao KA, Masterman KA, et al. Conservation and divergence in Toll-like receptor 4-regulated gene expression in primary human versus mouse macrophages. *Proc Natl Acad Sci U S A*. 2012;109(16):E944-53.
70. Lattin JE, Schroder K, Su AI, Walker JR, Zhang J, Wiltshire T, et al. Expression analysis of G Protein-Coupled Receptors in mouse macrophages. *Immunome Res*. 2008;4:5.
71. Raselli T, Wyss A, Gonzalez Alvarado MN, Weder B, Mamie C, Spalinger MR, et al. The Oxysterol Synthesising Enzyme CH25H Contributes to the Development of Intestinal Fibrosis. *J Crohns Colitis*. 2019;13(9):1186-200.
72. Guillemot-Legris O, Mutemberezi V, Buisseret B, Paquot A, Palmieri V, Bottemanne P, et al. Colitis Alters Oxysterol Metabolism and is Affected by 4beta-Hydroxycholesterol Administration. *J Crohns Colitis*. 2019;13(2):218-29.
73. Wu J, McDuffie JE, Song J, Harris MC, Raymond H, Chen Y, et al. LC/MS/MS Profiling of Tissue Oxysterols and its Application in Dextran Sodium Sulphate Induced Mouse Colitis Models. *Curr Top Med Chem*. 2017;17(24):2781-90.
74. Raselli T, Hearn T, Wyss A, Atrott K, Peter A, Frey-Wagner I, et al. Elevated oxysterol levels in human and mouse livers reflect nonalcoholic steatohepatitis. *J Lipid Res*. 2019;60(7):1270-83.
75. Willinger T. Oxysterols in intestinal immunity and inflammation. *J Intern Med*. 2019;285(4):367-80.
76. Bauman DR, Bitmansour AD, McDonald JG, Thompson BM, Liang G, Russell DW. 25-Hydroxycholesterol secreted by macrophages in response to Toll-like receptor activation suppresses immunoglobulin A production. *Proc Natl Acad Sci U S A*. 2009;106(39):16764-9.
77. Diczfalusy U, Olofsson KE, Carlsson AM, Gong M, Golenbock DT, Rooyackers O, et al. Marked upregulation of cholesterol 25-hydroxylase expression by lipopolysaccharide. *J Lipid Res*. 2009;50(11):2258-64.
78. Blanc M, Hsieh WY, Robertson KA, Kropp KA, Forster T, Shui G, et al. The transcription factor STAT-1 couples macrophage synthesis of 25-hydroxycholesterol to the interferon antiviral response. *Immunity*. 2013;38(1):106-18.
79. Liu SY, Aliyari R, Chikere K, Li G, Marsden MD, Smith JK, et al. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. *Immunity*. 2013;38(1):92-105.
80. Park K, Scott AL. Cholesterol 25-hydroxylase production by dendritic cells and macrophages is regulated by type I interferons. *J Leukoc Biol*. 2010;88(6):1081-7.
81. Abrams ME, Johnson KA, Perelman SS, Zhang LS, Endapally S, Mar KB, et al. Oxysterols provide innate immunity to bacterial infection by mobilizing cell surface accessible cholesterol. *Nat Microbiol*. 2020.
82. Reboldi A, Dang EV, McDonald JG, Liang G, Russell DW, Cyster JG. Inflammation. 25-Hydroxycholesterol suppresses interleukin-1-driven inflammation downstream of type I interferon. *Science*. 2014;345(6197):679-84.
83. Mufazalov IA, Schelmbauer C, Regen T, Kuschmann J, Wanke F, Gabriel LA, et al. IL-1 signaling is critical for expansion but not generation of autoreactive GM-CSF+ Th17 cells. *EMBO J*. 2017;36(1):102-15.

84. Jakobsson T, Treuter E, Gustafsson JA, Steffensen KR. Liver X receptor biology and pharmacology: new pathways, challenges and opportunities. *Trends Pharmacol Sci.* 2012;33(7):394-404.
85. Jakobsson T, Vedin LL, Hassan T, Venteclef N, Greco D, D'Amato M, et al. The oxysterol receptor LXRbeta protects against DSS- and TNBS-induced colitis in mice. *Mucosal Immunol.* 2014;7(6):1416-28.
86. Soroosh P, Wu J, Xue X, Song J, Sutton SW, Sablad M, et al. Oxysterols are agonist ligands of RORgamma and drive Th17 cell differentiation. *Proc Natl Acad Sci U S A.* 2014;111(33):12163-8.
87. Ueno A, Jeffery L, Kobayashi T, Hibi T, Ghosh S, Jijon H. Th17 plasticity and its relevance to inflammatory bowel disease. *J Autoimmun.* 2018;87:38-49.
88. Lochner M, Ohnmacht C, Presley L, Bruhns P, Si-Tahar M, Sawa S, et al. Microbiota-induced tertiary lymphoid tissues aggravate inflammatory disease in the absence of RORgamma t and LTi cells. *J Exp Med.* 2011;208(1):125-34.
89. Drayton DL, Ying X, Lee J, Lesslauer W, Ruddle NH. Ectopic LT alpha beta directs lymphoid organ neogenesis with concomitant expression of peripheral node addressin and a HEV-restricted sulfotransferase. *J Exp Med.* 2003;197(9):1153-63.
90. Pearson C, Thornton EE, McKenzie B, Schaupp AL, Huskens N, Griseri T, et al. ILC3 GM-CSF production and mobilisation orchestrate acute intestinal inflammation. *Elife.* 2016;5:e10066.
91. McNamee EN, Rivera-Nieves J. Ectopic Tertiary Lymphoid Tissue in Inflammatory Bowel Disease: Protective or Provocateur? *Front Immunol.* 2016;7:308.
92. Ota N, Wong K, Valdez PA, Zheng Y, Crellin NK, Diehl L, et al. IL-22 bridges the lymphotoxin pathway with the maintenance of colonic lymphoid structures during infection with *Citrobacter rodentium*. *Nat Immunol.* 2011;12(10):941-8.
93. McNamee EN, Masterson JC, Jedlicka P, Collins CB, Williams IR, Rivera-Nieves J. Ectopic lymphoid tissue alters the chemokine gradient, increases lymphocyte retention and exacerbates murine ileitis. *Gut.* 2013;62(1):53-62.
94. Spahn TW, Herbst H, Rennert PD, Luger N, Maaser C, Kraft M, et al. Induction of colitis in mice deficient of Peyer's patches and mesenteric lymph nodes is associated with increased disease severity and formation of colonic lymphoid patches. *Am J Pathol.* 2002;161(6):2273-82.
95. Sura R, Colombel JF, Van Kruiningen HJ. Lymphatics, tertiary lymphoid organs and the granulomas of Crohn's disease: an immunohistochemical study. *Aliment Pharmacol Ther.* 2011;33(8):930-9.
96. Cui Y, Lu SY, Xu J, Peng YS, Miao Q, Wang XQ, et al. Microscopic features of small bowel mucosa of patients with Crohn's disease. *BMC Gastroenterol.* 2019;19(1):232.
97. Marchesi F, Martin AP, Thirunarayanan N, Devany E, Mayer L, Grisotto MG, et al. CXCL13 expression in the gut promotes accumulation of IL-22-producing lymphoid tissue-inducer cells, and formation of isolated lymphoid follicles. *Mucosal Immunol.* 2009;2(6):486-94.
98. Sandborn WJ, Colombel JF, Enns R, Feagan BG, Hanauer SB, Lawrance IC, et al. Natalizumab induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2005;353(18):1912-25.
99. Sandborn WJ, Feagan BG, Rutgeerts P, Hanauer S, Colombel JF, Sands BE, et al. Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med.* 2013;369(8):711-21.

100. Feagan BG, Rutgeerts P, Sands BE, Hanauer S, Colombel JF, Sandborn WJ, et al. Vedolizumab as induction and maintenance therapy for ulcerative colitis. *N Engl J Med*. 2013;369(8):699-710.
101. Krupka N, Baumgart DC. Designing biologic selectivity for inflammatory bowel disease--role of vedolizumab. *Drug design, development and therapy*. 2015;9:147-54.
102. Bohra C, Sokol L, Dalia S. Progressive Multifocal Leukoencephalopathy and Monoclonal Antibodies: A Review. *Cancer Control*. 2017;24(4):1073274817729901.
103. Vermeire S, Colombel J, Feagan B, Sandborn W, Sands B, Danese S, et al. Long-term safety of vedolizumab in ulcerative colitis and Crohn's disease: final results from the GEMINI LTS study *Journal of Crohn's and Colitis*. 2019;ECCO oral presentation OP26.
104. Duc D, Vigne S, Pot C. Oxysterols in Autoimmunity. *Int J Mol Sci*. 2019;20(18).
105. Stepanovska B, Huwiler A. Targeting the S1P receptor signaling pathways as a promising approach for treatment of autoimmune and inflammatory diseases. *Pharmacol Res*. 2019.
106. Sandborn WJ, Feagan BG, Wolf DC, D'Haens G, Vermeire S, Hanauer SB, et al. Ozanimod Induction and Maintenance Treatment for Ulcerative Colitis. *N Engl J Med*. 2016;374(18):1754-62.
107. Peyrin-Biroulet L, Christopher R, Behan D, Lassen C. Modulation of sphingosine-1-phosphate in inflammatory bowel disease. *Autoimmun Rev*. 2017;16(5):495-503.
108. Feagan BG, Sandborn WJ, D'Haens G, Lee SD, Allez M, Fedorak RN, et al. Randomised clinical trial: vécirnon, an oral CCR9 antagonist, vs. placebo as induction therapy in active Crohn's disease. *Aliment Pharmacol Ther*. 2015;42(10):1170-81.
109. Biswas S, Bryant RV, Travis S. Interfering with leukocyte trafficking in Crohn's disease. *Best Pract Res Clin Gastroenterol*. 2019;38-39:101617.
110. Perez-Jeldres T, Tyler CJ, Boyer JD, Karuppuachamy T, Bamias G, Dulai PS, et al. Cell Trafficking Interference in Inflammatory Bowel Disease: Therapeutic Interventions Based on Basic Pathogenesis Concepts. *Inflamm Bowel Dis*. 2019;25(2):270-82.
111. Trivedi PJ, Adams DH. Chemokines and Chemokine Receptors as Therapeutic Targets in Inflammatory Bowel Disease; Pitfalls and Promise. *J Crohns Colitis*. 2018;12(12):1508.
112. Mayer L, Sandborn WJ, Stepanov Y, Geboes K, Hardi R, Yellin M, et al. Anti-IP-10 antibody (BMS-936557) for ulcerative colitis: a phase II randomised study. *Gut*. 2014;63(3):442-50.
113. Gessier F, Preuss I, Yin H, Rosenkilde MM, Laurent S, Endres R, et al. Identification and characterization of small molecule modulators of the Epstein-Barr virus-induced gene 2 (EBI2) receptor. *J Med Chem*. 2014;57(8):3358-68.
114. Braden K, Giancotti LA, Chen Z, DeLeon C, Latzo N, Boehm T, et al. GPR183-oxysterol axis in spinal cord contributes to neuropathic pain. *J Pharmacol Exp Ther*. 2020.
115. Harding SD, Sharman JL, Faccenda E, Southan C, Pawson AJ, Ireland S, et al. The IUPHAR/BPS Guide to PHARMACOLOGY in 2018: updates and expansion to encompass the new guide to IMMUNOPHARMACOLOGY. *Nucleic acids research*. 2018;46(D1):D1091-D106.




Figure 1: Biosynthesis and degradation of oxysterols.

Oxysterol biosynthesis starts with oxidation at the 25-position by the enzyme cholesterol 25-hydroxylase (CH25H) or at the 27-position by cytochrome p450 family 27 member A1 (CYP27A1), yielding 25-hydroxycholesterol (25-HC) and 27-hydroxycholesterol (27-HC), respectively. Further 7 α -hydroxylation by CYP7B1 results in production of 7 α ,25-diHC and 7 α ,27-diHC, respectively. Oxysterols are ultimately degraded to bile acids by the activity of hydroxy- Δ^5 -steroid dehydrogenase, 3 β - and steroid Δ^5 -isomerase 7 (HSD3B7).




Figure 2: GPR183 dependent movements of immune cells in secondary lymphoid organs

B cell follicles with germinal centre (orange) and the T cell area are indicated. A gradient of the GPR183 ligand 7 α ,25-diHC is expected in secondary lymphoid organs according to expression levels of the 7 α ,25-diHC synthesizing enzymes Cyp7b1 and Ch25h. Highest 7 α ,25-diHC concentrations are expected in the outer follicle (dark green). GPR183 expressing B cells, T cells and dendritic cells follow the 7 α ,25-diHC gradient (red arrows) and some B cells move to the outer follicle (light blue circle). For other immune cells with concurrent expression of other chemokine receptors (e.g. CCR7, purple arrows) positioning reflects the effects of more than one cytokine and B cells are also found in the interfollicular area (dark blue circles). GPR183 also supports positioning of T cells and DCs (not indicated).




Figure 3: Schematic view of lymphoid structures in the colon and the small intestine.

- (A) Overview of the small intestine and the colon with intramucosal solitary intestinal lymphoid tissue (SILT) and colonic SILT (cSILT) as well as larger mucosal and submucosal Peyer's patches and colonic patches (CLP)
- (B) Schematic view of location of lymphoid structures and its cellular content. Please note the strict intramucosal of cSILT comprising small cryptopatches and larger isolated lymphoid tissue




Figure 4: Key structures of the colonic immune system.

Left panel: complete mouse colon as a “Swiss roll”. Inserts indicate colonic patches (CLP) and solitary intestinal lymphoid tissue (SILT), shown on the right. While CLPs replace mucosa and submucosa, SILTs are strict mucosal structures, respecting the tunica muscularis mucosae (arrows). Cryptopatches are small SILTs comprising mainly lymphoid tissue inducer (LTi) cells and dendritic cells (DCs) but lack B cells (not shown). Acquisition of B cells yields larger SILTs, called intestinal lymphoid follicles (ILF).




Figure 5: Architecture of the GPR183/ UBAC2 gene locus on chromosome 13

The UBAC2 gene (green) is located on the forward (fwd) strand of chromosome 13, while the GPR183 gene (pink) is located on the reverse (rev) strand. Neighbouring genes encoding G-protein coupled receptor 18 (GPR18) and UBAC2 antisense RNA 1 (UBAC2-AS1) are also indicated. The major transcript of the respective genes with its introns (horizontal line) and exons (rectangles or vertical lines) are indicated in grey. Relevant SNPs (for instance the IBD-SNP rs9557195, the psoriasis-SNP rs9513593 or the Behçet's disease-SNPs rs3825427, rs7999348) are highlighted with the colour of the associated gene.

Table 1: Cellular targets of oxysterols and downstream effects.

Oxysterol ligand	Cellular target	Exemplary downstream effects and effects in the intestine (if applicable).	Reference
7 β ,27-diHC, 7 α ,27-diHC	ROR γ t \uparrow	Th17, ILC3 differentiation, induction of SILTs in the colon	(3, 38-42, 73)
25-HC, 27-HC	LXR- α , LXR- β \uparrow	Anti-inflammatory effects in colitis, cellular metabolism and immunity	(71, 72, 109)
	INSIG \uparrow , SREBP \downarrow	Inhibition of cholesterol synthesis, effects in the intestine unclear	(110)
25-HC	Inflammasome \downarrow	Inflammasome inhibition, reduced production of IL-1 and IL-18	(69)
	Antibacterial defence \uparrow	Reduction of accessible membrane cholesterol. Inhibits replication of <i>L. monocytogenes</i> , <i>S. flexneri</i>	(68)
	Antiviral defence \uparrow	Inhibits replication of a number of viruses	(65, 66)
7 α ,25-diHC, 7 α ,27-diHC	GPR183 \uparrow	Positioning of B cells, T cells, DCs, ILC3s. Formation of SILTs in the colon, pro-inflammatory effects in colitis (see text for details).	(2, 3, 5, 8, 9, 26-28, 34)